In an acute pseudogout flare, should a patient receive a ketorolac (Toradol) injection, or be given ketorolac in addition to oral prednisone for pain control?

Ketorolac (Toradol) for Acute Pseudogout: Use as Monotherapy, Not in Combination with Prednisone

For acute pseudogout pain control, use either ketorolac OR prednisone as monotherapy—do not combine NSAIDs with systemic corticosteroids due to synergistic gastrointestinal toxicity risk. 1

Treatment Algorithm for Acute Pseudogout

First-Line Monotherapy Options (Choose ONE):

1. Oral Prednisone (Preferred for most patients)

• Dose: 0.5 mg/kg/day for 5-10 days, then stop 1
• Alternative: 2-5 days at full dose, then taper over 7-10 days 1
• Safer profile than NSAIDs with fewer adverse effects 2
• Consider first-line unless contraindications exist (systemic fungal infection, uncontrolled diabetes) 2

2. Ketorolac (Toradol) Injection

• Single IM dose: 60 mg for patients <65 years; 30 mg for patients ≥65 years or <50 kg 3
• Single IV dose: 30 mg for patients <65 years; 15 mg for patients ≥65 years or <50 kg 3
• Maximum duration: 5 days total (IV/IM + oral combined) 3
• Contraindications: Advanced renal impairment, active peptic ulcer disease, GI bleeding history, cardiovascular disease, concurrent aspirin/NSAID use 3

3. Other NSAIDs (if ketorolac unavailable)

• Full FDA-approved doses until attack resolves 1
• Examples: Naproxen, indomethacin 1

When NOT to Combine Ketorolac with Prednisone:

The 2012 ACR guidelines explicitly state that NSAIDs and systemic corticosteroids should NOT be used in combination due to concerns about synergistic gastrointestinal tract toxicity 1. This recommendation was specifically excluded from voting by the task force panel due to safety concerns.

Acceptable Combination Therapy (for severe/polyarticular attacks):

If monotherapy fails after 24 hours (<20% pain improvement) or 48+ hours (<50% improvement) 1, acceptable combinations include:

• Colchicine + NSAIDs
• Oral corticosteroids + colchicine
• Intra-articular steroids + any other modality 1

But NOT NSAIDs + systemic corticosteroids 1

Critical Safety Considerations for Ketorolac:

Absolute Contraindications 3:

• Advanced renal impairment or volume depletion
• Active peptic ulcer disease or GI bleeding history
• Suspected cerebrovascular bleeding
• Concurrent aspirin or NSAID use
• Coronary artery bypass graft surgery setting
• Pregnancy/labor

High-Risk Populations Requiring Dose Adjustment 3:

• Age ≥65 years: Reduce dose by 50%
• Weight <50 kg: Reduce dose by 50%
• Renal impairment: Contraindicated if advanced; use caution otherwise
• Maximum daily dose: 120 mg for standard patients; 60 mg for high-risk patients 3

Practical Clinical Approach:

Step 1: Confirm pseudogout diagnosis (synovial fluid analysis showing rhomboid-shaped calcium pyrophosphate crystals) 4, 5

Step 2: Assess patient risk factors:

• Renal function (ketorolac contraindicated if impaired)
• GI bleeding history (avoid ketorolac)
• Cardiovascular disease (avoid ketorolac)
• Diabetes control (use prednisone cautiously)
• Age and weight (adjust ketorolac dosing)

Step 3: Choose monotherapy:

• Default to prednisone 0.5 mg/kg/day unless contraindicated 2
• Use ketorolac if corticosteroids contraindicated AND patient meets safety criteria
• Consider intra-articular corticosteroid injection for monoarticular involvement 6

Step 4: Reassess at 24 hours:

• If <20% pain improvement, switch to alternative monotherapy or add colchicine 1
• Do NOT add systemic corticosteroid to NSAID 1

Common Pitfalls to Avoid:

1. Combining ketorolac with prednisone: Increases GI bleeding risk without additional benefit 1
2. Exceeding 5-day ketorolac duration: Significantly increases serious adverse events without improved efficacy 3
3. Using ketorolac in elderly without dose reduction: Standard doses cause excessive toxicity in patients ≥65 years 3
4. Ignoring renal function: Ketorolac is absolutely contraindicated in advanced renal impairment 3